tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2021 May 12;101429.
doi: 10.1016/j.rmcr.2021.101429. Online ahead of print.
Pulmonary arterial hypertension post COVID-19: A sequala of SARS-CoV-2 infection?
Abdul Wali Khan[SUP] 1 [/SUP], Irfan Ullah[SUP] 2 [/SUP], Kiran Shafiq Khan[SUP] 3 [/SUP], Muhammad Junaid Tahir[SUP] 4 5 [/SUP], Sri Masyeni[SUP] 6 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP]
Affiliations
Abstract
It has been suggested that pulmonary arterial hypertension (PAH) could be a potential sequela of coronavirus disease 2019 (COVID-19) in particular in those with hypertension; however, development of PAH after the course of COVID-19 in normotensive individuals are rarely reported. Here, we report a patient who developed PAH two months post-COVID-19. The patient was a 55-year-old female and normotensive, tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developed mild respiratory distress syndrome and necessitated continuous positive airway pressure during the treatment in the hospital. After two months discharged from the hospital with RT-PCR negative for SARS-CoV-2, the patient presented with exertional dyspnea, dry cough, fatigue and episodes of syncope during exertion. Based on clinical presentation, electrocardiography, computed tomography, and transthoracic echocardiography assessment, PAH diagnosis was made. To our knowledge, this is a rare PAH case and this highlights the possible of PAH as sequala that might present in post COVID-19 patients.
Keywords: COVID-19; PAH; complication; pulmonary arterial hypertension; sequala.
. 2021 May 12;101429.
doi: 10.1016/j.rmcr.2021.101429. Online ahead of print.
Pulmonary arterial hypertension post COVID-19: A sequala of SARS-CoV-2 infection?
Abdul Wali Khan[SUP] 1 [/SUP], Irfan Ullah[SUP] 2 [/SUP], Kiran Shafiq Khan[SUP] 3 [/SUP], Muhammad Junaid Tahir[SUP] 4 5 [/SUP], Sri Masyeni[SUP] 6 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP]
Affiliations
- PMID: 33996435
- PMCID: PMC8114592
- DOI: 10.1016/j.rmcr.2021.101429
Abstract
It has been suggested that pulmonary arterial hypertension (PAH) could be a potential sequela of coronavirus disease 2019 (COVID-19) in particular in those with hypertension; however, development of PAH after the course of COVID-19 in normotensive individuals are rarely reported. Here, we report a patient who developed PAH two months post-COVID-19. The patient was a 55-year-old female and normotensive, tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developed mild respiratory distress syndrome and necessitated continuous positive airway pressure during the treatment in the hospital. After two months discharged from the hospital with RT-PCR negative for SARS-CoV-2, the patient presented with exertional dyspnea, dry cough, fatigue and episodes of syncope during exertion. Based on clinical presentation, electrocardiography, computed tomography, and transthoracic echocardiography assessment, PAH diagnosis was made. To our knowledge, this is a rare PAH case and this highlights the possible of PAH as sequala that might present in post COVID-19 patients.
Keywords: COVID-19; PAH; complication; pulmonary arterial hypertension; sequala.